When physical and mental health problems co-occur and money gets tight, which prescriptions go unfilled?April 08, 2009A new study points to a troubling connection between out-of-pocket expenses for people contending with both physical illnesses and depression, affecting access to antidepressant treatment. Dr. Carolyn Dewa, head of the Work and Well-being Research and Evaluation Program at the Centre of Addiction and Mental Health (CAMH), and her team explored whether the amount of money spent on medication before a disability episode impacts medication use among workers on depression-related disability. This study built on previous research that revealed workers on depression-related short-term disability improved with antidepressant treatment. "The results raised concerns about the treatment choices people are making," Dr. Dewa said. "As an example, if a worker's prior out-of-pocket expenses for medication associated with heart disease were $500, the probability of filling an antidepressant prescription was only 40 percent." The CAMH team analyzed administrative disability data for three large firms with approximately 63,000 employees nationwide. The analysis, published in Healthcare Policy revealed that workers on depression-related short-term disability are more likely to fill a prescription for antidepressant medication if they have previously purchased antidepressants. This suggests that the medication is viewed as necessary, which may point to increased adherence to antidepressants, an issue that is frequently of concern in depression treatment. At the same time, a worker on depression-related short-term disability is less likely to fill a prescription for antidepressant medication if the worker already is paying high out-of-pocket costs for medications to treat physical disorders such as heart disease or asthma (about 50 percent of employees studied had a co-morbid chronic physical disorder). This phenomenon may be a barrier to accessing antidepressant treatment, which could delay taking necessary medication, impacting not only a person's recovery, but also a company's bottom line. Approximately one third of work-related productivity losses can be attributed to an employee being either unproductive or unable to function at full capacity because of depression. While recommended use of anti-depressants is associated with increased productivity and decreased disability, depression treatment is often complicated by physical disorders (e.g. heart disease, ulcers, hypertension, and asthma) that also require prescription drug treatment. According to Dr. Dewa, a delay in use could cost an average of $2,924 extra (based on the average hourly wage of $21.66) per worker on depression-related short-term disability. As Dr. Dewa explains, these findings highlight the dilemma faced by many employers - the desire to control rising costs of prescription drug benefits must be balanced with the fact that it's important not to create barriers to treatment. More research is needed to evaluate if drug benefits should be changed for workers on depression-related disability leave, especially those with a chronic physical condition. Centre for Addiction and Mental Health |
|||||||||||||||||||||
| Related Antidepressant Treatment Current Events and Antidepressant Treatment News Articles Popular antidepressant associated with a dramatic increase in suicidal thoughts amongst men Nortriptyline has been found to cause a ten-fold increase in suicidal thoughts in men when compared to its competitor escitalopram. These findings are published in the open access journal BMC Medicine. UCLA researchers develop biomarker for rapid relief of major depression It is a long, slow slog to treat major depression. Many antidepressant medications are available, but no single biomarker or diagnostic test exists to predict which one is right for an individual. Ketamine reduces suicidality in depressed patients Drug treatment options for depression can take weeks for the beneficial effects to emerge, which is clearly inadequate for those at immediate risk of suicide. New mouse model of depression/anxiety enhances understanding of antidepressant drugs A recent study finds that the antidepressant effects of drugs like Prozac involve both neurogenesis-dependent and -independent mechanisms, a finding that may lead to development of better treatments for depression and anxiety. How men and women cope differently with stress traced by Hebrew University researchers Can people's differing reactions to situations of stress be attributed at least in part to genetic differences and do those differences affect men and women in different ways - with the edge seemingly favoring the women? Research conducted at the Hebrew University of Jerusalem would seem to indicate that the answer to both questions is yes. Antidepressants in suicide prevention Antidepressants are the cornerstone of treatment of depressive disorders in health care. Their efficacy in treating depression is undisputable, although it leaves room for improvement. Use of sildenafil associated with improvement in antidepressant-related sexual dysfunction in women Women with sexual dysfunction caused by the use of antidepressants experienced a reduction in adverse sexual effects with use of sildenafil, commonly known as the erectile dysfunction medication Viagra. Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time. New study replicates association between genetic variation and antidepressant treatment response Pharmacogenetics, the study of genetic variation that influences an individual's response to drugs, is an important and growing focus in all of medical research, including psychiatry. NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression New findings from research supported by NARSAD, the world's leading charity dedicated to mental health research, and conducted by Harvard-affiliated scientists are providing important clues into how genes work to impair various aspects of attention, memory and perception -- the behaviors associated with many psychiatric illnesses, such as schizophrenia, bipolar disorder and depression. More Antidepressant Treatment Current Events and Antidepressant Treatment News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||